Sponsored by Astellas Pharma

Optimising OAB management: Learnings, current strategies and future outlook

This symposium is focused on the management of Overactive Bladder (OAB) and offers an opportunity to explore learnings from past and present knowledge. We will also explore how present and future advancements will contribute to optimize OAB management and improve OAB patient experience.

The symposium will feature distinguished experts who will review the disease burden and the significant impact of OAB on patients' lives. Attendees will gain insights into the roles of various stakeholders in improving continence care and learn about global initiatives aimed at advancing this field.

A key focus will be the introduction of Mirabegron, the first beta-3 agonist, highlighting its innovative mechanism of action and its extensive clinical development. The session will cover Mirabegron’s efficacy and safety across diverse OAB subpopulations, supported by over ten years of real-world clinical experience.

Despite progress in OAB management, challenges remain. Our experts will explore how new approaches, such as OAB phenotyping, predictive models, and artificial intelligence, can further refine patient care.

This symposium is an opportunity for healthcare professionals to update their knowledge and engage in meaningful discussions about the future of OAB management.